Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence

Clinical Pharmacokinetics

Volumn 44, Issue 7, 2005, Pages 661-680

  Elkader, Alexander ^a   Sproule, Beth ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CARBAMAZEPINE; CYTOCHROME P450 3A4; FLUOXETINE; FLUVOXAMINE; IMIDAZOLE; INDINAVIR; KETOCONAZOLE; LEVACETYLMETHADOL; METHADONE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NEFAZODONE; PHENOBARBITAL; PHENYTOIN; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR;

AREA UNDER THE CURVE; BIOEQUIVALENCE; BREAST MILK; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DEALKYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG URINE LEVEL; ENZYME INHIBITION; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MATERNAL PLASMA; OPIATE ADDICTION; PAPAVER SOMNIFERUM; PREGNANCY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TABLET FORMULATION;

BIOLOGICAL AVAILABILITY; BUPRENORPHINE; HUMANS; METABOLIC CLEARANCE RATE; OPIOID-RELATED DISORDERS;

EID: 22244462451     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544070-00001     Document Type: Review

References (92)

1. Rothman RB, Ni Q, Xu H. A review of the binding literature. In: Cowan A, Lewis JW, editors. Combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 19-29
2. Marquet P. Pharmacology of high dose buprenorphine. In: Kintz P, Marquet P, editors. Buprenorphine therapy of opiate addiction. Totowa (NJ): Humana Press, 2002: 1-11
3. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55 (5): 569-80
4. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France [letter]. JAMA 2001; 285 (1): 45
5. Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K[+] currents. J Pharmacol Exp Ther 2002; 303 (2): 688-94
6. Petry NM, Bickel WK, Badger GJ. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clin Pharmacol Ther 1999; 66 (3): 306-14
7. Mattick RP, Ali R, White JM, et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98: 441-52
8. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 1978; 35: 501-16
9. Jasinski DR, Preston KL. Laboratory studies of buprenorphine in opioid abusers. In: Cowan A, Lewis JW, editors. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 189-211
10. Strain EC, Stitzer ML, Liebson IA, et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151 (7): 1025-30
11. Johnson RE, Eissenberg T, Stitzer ML, et al. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40: 17-25
12. Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94: 1337-47
13. Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. N Engl J Med 2000; 343: 1290-7
14. Petitjean S, Stohler R, Deglon JJ, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001; 62: 97-104
15. Ahmadi J. Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat 2003; 24: 217-20
16. Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000; 61: 85-94
17. Stoller KB, Bigelow GE, Walsh SL, et al. Effects of buprenorphine/ naloxone in opioid-dependent humans. Psychopharmacology 2001; 154: 230-42
18. Weinhold LL, Preston KL, Farre M, et al. Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend 1992; 30: 263-74
19. Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 2002; 303 (2): 695-703
20. Preston KL, Bigelow GE, Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology 1988; 94: 484-90
21. Mendelson J, Jones RT, Fernandez I, et al. Buprenorphine and naloxone interaction in opiate-dependent volunteers. Clin Pharmacol Ther 1996; 60: 105-14
22. Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry 1997; 41 (11): 1095-101
23. Fudala PJ, Yu E, Macfadden W, et al. Effects of buprenorphine and naloxone in morphine stabilized opioid addicts. Drug Alcohol Depend 1998; 50: 1-8
24. Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology 1999; 141: 37-46
25. Reckitt Benckiser. Buprenorphine monograph [online]. Available from URL: http://www.fda.gov/cder/foi/label/2002/20732-lbl.pdf. [Accessed 2005 May 17]
26. Cowan A. Update of the general pharmacology of buprenorphine. In: Cowan A, Lewis JW, editors. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 189-211
27. Bartlett AJ, Lloyd-Jones JG, Rance MJ, et al. The radioimmunoassay of buprenorphine. Eur J Clin Pharmacol 1980; 18: 339-45
28. Cirimele V. Separative techniques for determination of buprenorphine. In: Kintz P, Marquet P, editors. Buprenorphine therapy of opiate addiction. Totowa (NJ): Humana Press, 2002: 89-108
29. Kuhlman Jr JJ, Magluilo Jr J, Cone E, et al. Simultaneous assay of buprenorphine and norbuprenorphine by negative chemical ionization tandem mass spectrometry. J Anal Toxicol 1996; 20: 229-35
30. Everhart ET, Cheung P, Shwonek P, et al. Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to depenpharmacokinetics of sublingual buprenorphine. Clin Chem 1997; 43 (12): 2292-302
31. Moody DE, Slawson MH, Strain EC, et al. A liquid chromatographic- electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 2002; 306: 31-9
32. Stinchcomb AL, Paliwal A, Dua R, et al. Permeation of buprenorphine and its 3-alkyl-ester prodrugs through skin. Pharm Res 1996; 13 (10): 1519-23
33. Radbruch L, Vielvoye-Kerkmeer A. Buprenorphine TDS: the clinical development rationale and results. Int J Clin Pract Suppl 2003; 133: 15-8
34. Kuhlman Jr JJ, Lalani S, Magluilo Jr J, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996; 20 (6): 369-78
35. Mendelson J, Upton RA, Everhart ET, et al. Bioavailability of sublingual buprenorphine. J Clin Pharmacol 1997; 37 (1): 31-7
36. Nath RP, Upton RA, Everhart ET, et al. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 1999; 39 (6): 619-23
37. Schuh KJ, Johanson CE. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend 1999; 56 (1): 55-60
38. Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availaby bility, plasma concentrations, and antagonist blockade in hero-in-dependent volunteers. Neuropsychopharmacology 2003 Nov; 28 (11): 2000-9
39. Zubieta JK, Greenwald MK, Lombardi U, et al. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 2000; 23: 326-34
40. Bullingham RES, McQuay HJ, Porter EJB, et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Pharmacol 1982; 13: 665-73
41. Bullingham RES, McQuay HJ, Dwyer D, et al. Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol 1981; 12: 117-22
42. Bullingham RES, McQuay HJ, Moore RA, et al. Buprenorphine kinetics. Clin Pharmacol Ther 1980; 28 (5): 667-72
43. Kuhlman Jr JJ, Levine B, Johnson RE, et al. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93 (4): 549-59
44. Strain EC, Moody DE, Stoller KB, et al. Relative bioavailability of different formulations under chronic dosing conditions. Drug Alcohol Depend 2004; 74: 37-43
45. Harris DS, Mendelson JE, Lin ET, et al. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 2004; 43 (5): 329-40
46. McAleer SD, Mills RJ, Polack T, et al. Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naive healthy male volunteers under a naltrexone block. Drug Alcohol Depend 2003; 72: 75-83
47. Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 44 (3): 335-42
48. Cone EJ, Dickerson SL, Darwin WD, et al. Elevated drug saliva levels suggests a "depot-like" effect in subjects treated with sublingual buprenorphine. NIDA Res Monogr 1991; 105: 569
49. Lopatko OV, White JM, Huber A, et al. Opioid effects and opioid withdrawal during a 24h dosing interval in patients maintained on buprenorphine. Drug Alcohol Depend 2003; 69: 317-22
50. Walter DS, Inturrisi CE. Absorption, distribution, metabolism and excretion of buprenorphine in animals and humans. In: Cowan A, Lewis JW, editors. Buprenorphine: combating drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 113-35
51. Gaulier JM, Marquet P, Lacassie E, et al. Fatal intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci 2000; 45 (1): 226-8
52. Cone EJ, Gorodetzky CW, Yousenfnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984; 12 (5): 577-81
53. Ohtani M, Kotaki H, Sawada Y, et al. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272 (2): 505-10
54. Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl 2003; 133: 3-8
55. Iribarne C, Picart D, Dreano Y, et al. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997; 60 (22): 1953-64
56. Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1998; 26: 818-21
57. Jakab F, Rath Z, Schmal F, et al. Intraoperative estimation of liver blood flow in man. Acta Chir Hung 1992; 33 (3-4): 367-74
58. Epstein RM, Deutsch S, Cooperman LH, et al. Splanchnic circulation during halothane anesthesia and hypercapnia in normal man. Anesthesiology 1966; 27 (5): 654-61
59. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 3rd ed. Stockholm: Swiss Pharmaceutical Press, 2000
60. Brewster D, Humphrey MJ, McLeavy MA. Biliary excretion, metabolism, and enterohepatic circulation of buprenorphine. Xenobiotica 1981; 11 (3): 189-96
61. Blom Y, Bondesson U. Analysis of buprenorphine and its N-dealkylated metabolite in plasma and urine by selected-ion monitoring. J Chromatogr 1985; 338: 89-98
62. Preston KL, Bigelow GE, Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 1990; 25: 27-34
63. Summerfield RJ, Allen MC, Moore RA, et al. Buprenorphine in end stage renal failure [letter]. Anaesthesia 1986; 41: 914
64. Hand CW, Sear JW, Uppington J, et al. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990; 64 (3): 276-82
65. George J, Murray M, Byth K, et al. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995; 21 (1): 120-8
66. Yang LQ, Li SJ, Cao YF, et al. Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 2003; 9 (2): 359-63
67. Petry NM, Bickel WK, Piasecki D, et al. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000; 9 (3): 265-9
68. Johnson RE, Jones RT, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003; 70: S87-101
69. Marquet P, Chevrel J, Lavignasse P, et al. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther 1997; 62 (5): 569-71
70. Johnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001; 63: 97-103
71. Oesterheld JR. A review of developmental aspects of cytochrome P450. J Child Adolesc Psychopharmacol 1998; 8 (3): 161-74
72. Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625-34
73. Ibrahim RB, Wilson JG, Thorsby ME, et al. Effect of buprenorphine on CYP 3A activity in rat and human liver microsomes. Life Sci 2000; 66 (14): 1293-8
74. Umehara K, Shimokawa Y, Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull 2002; 25 (2): 682-5
75. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996; 86 (5): 642-54
76. Fischer B, Medved W, Gliksman L, et al. Illicit opiates in Toronto: a profile of current users. Addict Res 1999; 7: 377-415
77. Bruneau J, Lamothe F, Soto J, et al. Sex-specific determinants of HIV infection among injection drug users in Montreal. CMAJ 2001; 164 (6): 763-73
78. Steffen T, Blattler R, Gutzwiller F, et al. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health 2001; 11: 425-30
79. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26 (3): 257-60
80. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990; 264 (19): 2511-8
81. Iribarne C, Picart D, Dreano Y, et al. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol 1998; 12: 194-9
82. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998 Oct; 22 (6): 430-4
83. Reynaud M, Petit G, Potard D, et al. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998 Sep; 93 (9): 1385-92
84. Klintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121: 65-9
85. Barnas C, Rossman M, Roessler H, et al. Benzodiazepine and other psychotropic drugs abused by patients in methadone maintenance program: familiarity and preference. J Clin Psychopharmacol 1992; 12: 397-402
86. Kilicarslan T, Haining RL, Busto U, et al. Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metab Dispos 2000; 29 (4): 460-5
87. Kilicarslan T, Sellers EM. Lack of interaction of buprenorphine with flunitrazepam metabolism. Am J Psychiatry 2000; 157: 1164-6
88. Compton PA, Wesson DR, Charuvastra VC, et al. Buprenorphine as a pharmacotherapy for opiate addiction: what dose provides a therapeutic response? Am J Addict 1996; 5: 220-30
89. Schottenfeld RS, Pakes J, Ziedonis D, et al. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry 1993; 34: 66-74
90. Petry NM, Bickel WK, Badger GJ. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. Addiction 2001; 96 (6): 823-834
91. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine aintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93 (4): 475-86
92. Dyer KR, Foster DJR, White JM, et al. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999; 65 (6): 685-94